The Antiemetic Effects of Increased Splanchnic Perfusion, Induced by the Gut Hormone GIP, in Healthy Individuals

What Was Tested

In this not phased trial, researchers set out to test GIP (Gastric Inhibitory Polypeptide).

GIP is naturally released after meals and is administered intravenously to healthy participants during the experiment.

Nausea is induced using either glucagon-like peptide 1 (GLP-1), another gut hormone, or apomorphine, a medication known to trigger nausea.

It had five arms (groups): s.c. injection of GLP-1 and infusion of saline (active comparator), s.c. injection of GLP-1 and infusion of GIP (active comparator), s.c. injection of apomorphine and infusion of saline (active comparator), s.c. injection of apormorphine and infusion of GIP (active comparator) and s.c. injection of saline and infusion of GIP (placebo comparator).

The registry classes the interventions as other.

Who Took Part

14 planned participants were the target.

It was open to people of any sex aged from 18 years up to 60 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Men or women, age of 18-60 years. BMI between 19-27 kg/m2 (both included).

The full record lists 3 inclusion and 10 exclusion criteria; among the exclusions: current or past treatment with glp-1 or gip/glp-1 receptor-targeting compounds within the last six months; gastrointestinal disorders that the investigator evaluates could interfere with induction of nausea (e.g. gastroparesis, functional dyspepsia and gi surgery); neurological disorders affecting nausea (e.g. severe migraines and neuropathy).

How the Study Was Run

Design: randomized, crossover and double-blind.

Random assignment meant chance, not the researchers, decided who got GIP (Gastric Inhibitory Polypeptide) and who got the comparison, which limits bias.

Each person switched between GIP (Gastric Inhibitory Polypeptide) and the comparison at some point, usually with a gap in between.

Neither the participants nor the staff measuring them knew who was on GIP (Gastric Inhibitory Polypeptide), so expectations could not easily colour the readings.

Those kept unaware of assignments: participant and investigator.

It started in 2026-05-19 with completion listed for 2026-11-30.

It ran at 1 site in Denmark.

Its stated primary purpose is supportive care.

What Was Measured

The main thing measured (primary outcome): Change in GLP-1 induced nausea intensity (time frame: From enrollment to the end of treatment at up to 12 weeks).

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of GIP (Gastric Inhibitory Polypeptide) in 14 people.

Its size is small, so on its own it can only give an early look.

Its status is enrolling by invitation; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.